10.14.02: Private Healthcare Issue
Two analysts and top management from thirty sector firms examine the Private Healthcare sector in this 108 - page Private Healthcare Issue from The Wall Street Transcript.
  1. Funding Biotech Companies - In an in-depth (3,000 words) Analyst interview, Fariba F. Ghodsian, a Managing Director and Director of Healthcare Research at Roth Capital Partners, examines the outlook for the sector and shares specific stock recommendations.
  2. Funding Private Healthcare - In an in-depth (2,700 words) Analyst interview, Carl L. Gordon, a founding General Partner of OrbiMed Advisors LLC, examines the outlook for the sector and shares specific stock recommendations.
  3. CEO interviews (average 2,500 words). Top management of thirty - sector firms examine the outlook for their firm and the sector. Firms include:
    Elusys Therapeutics, MediciNova, Acorda Therapeutics, AnVil, Atherotech, Barrier Therapeutics, Cellular Genomics, ChemGenex Therapeutics, Consensus Pharmaceuticals, DrugAbuse Sciences, EXIMIAS Pharmaceutical, Fast Track Systems, Focus Technologies, GTx, Integrated Biosystems, LifeSpan Biosciences, MicroTest Laboratories, Mojave, Therapeutics, Peptor, Protarga Systems, PTC Therapeutics, Quorex Pharmaceuticals, Stereotaxis, SurroMed, Therion Biologics, TolerRx, U.S. Genomics, VNUS Medical Technologies, Zymark
    4. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been read and used by investors and industry executives for nearly 40 years. It's a vital and unique tool for doing company and industry research - as part of a stock purchase decision or as part of a market analysis.

Investors:
TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. Find out where they agree, and where they disagree on stock recommendations. Money manager interviews provide the view from the buy-side. And CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Industry Executives:
Get the insider view on the sector from Wall Street Analysts and Company CEO's. Company strategies, growth ambitions, new products and markets, management - these and much more are discussed by the top executives in the industry. TWST's reports should be a key part of any industry research.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE